Imeik Technology Development (300896.SZ) Annual Report for 2024: Revenue breaks 3 billion for the first time, generous dividends to investors.

On the evening of March 19, 2025, Imeik Technology Development (300896.SZ) released its annual report for 2024, with both revenue and profit reaching a record high. The operating income was approximately 3.026 billion yuan, a year-on-year increase of 5.45%; the net profit attributable to equity holders was approximately 1.958 billion yuan, a year-on-year increase of 5.33%. At the same time, the company plans to distribute a cash dividend of 38 yuan (including tax) per 10 shares to all shareholders, totaling 1.145 billion yuan (including tax), the highest cash dividend amount in history, accounting for 58.51% of the full-year net profit. In 2024, Imeik Technology Development followed market consumption trends, utilized its advantages in product line richness and efficient resource allocation, deepened cooperation with customers, continuously enhanced market visibility and influence, and promoted simultaneous growth of solution and gel injection products. Among them, "Hai Ti" has sold over 20 million units in the neck wrinkle repair field, helping solution injection products achieve revenue of approximately 1.744 billion yuan, a year-on-year increase of 4.40%; with "Double Angel" as its flagship, gel injection products achieved revenue of approximately 1.216 billion yuan, a year-on-year increase of 5.01%. In recent years, through continuous strengthening of research and development and technological innovation, Imeik Technology Development has established a complete research and development system in the medical beauty industry, with outstanding research and development innovation capabilities and efficient commercialization abilities in the field of dermal fillers. In the past year, the company invested approximately 304 million yuan in research and development, accounting for 10.04% of total revenue. As of the end of 2024, it owned 163 valid authorized patents, including 49 invention patents. In terms of technological applications, Imeik Technology Development has applied multiple patented technologies to molded products, including the first commercialized PVA microsphere long-lasting filling effect dermal filler, the first commercialized dermal filler containing lidocaine, the first dermal filler containing L-peptide and amino acids, and the first dermal filler containing PLLA microspheres. The research and development innovation capabilities have been highly recognized by the market. In terms of commercialization, the company has successfully industrialized a series of dermal fillers based on hyaluronic acid sodium, dermal fillers based on polylactic acid, and PDO face embedding lines, while also developing biological medical products such as recombinant proteins and peptides. Currently, the company's Simu Gelatine peptide injection solution, deoxycholic acid injection solution, and recombinant hyaluronidase have obtained clinical trial approvals from the National Medical Products Administration; applications for the market approval of injectable type A botulinum toxin, minoxidil lotion, and lidocaine prilocaine cream have been accepted and entered the review stage. Furthermore, by the end of 2024, Imeik Technology Development's total cash, bonds, and trading financial assets amounted to approximately 6 billion yuan, with an asset-liability ratio reduced to 4.68%, further optimized from 2023, laying a solid financial foundation for its domestic and international strategic mergers and acquisitions and long-term sustainable development. Looking ahead, the growth potential of the Chinese medical beauty consumer market remains immense, with the industry maintaining steady growth momentum. According to Frost & Sullivan data, the size of the Chinese medical beauty market is expected to reach 638.2 billion yuan by 2030, with a compound annual growth rate of 14.5% from 2021 to 2030. According to the company's plan, in the future, Imeik Technology Development will seize opportunities, actively expand market coverage, continuously optimize service quality, increase research and development investment, enhance production efficiency, and actively promote digital transformation, embrace the industry's wave of change, and comprehensively promote the steady development of the company.